SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is surging following a positive clinical update that highlights an annual recurrence rate of less than 1% in the open-label arm of its Phase III trial, fueling community optimism about the company's competitive position. Investors are actively discussing the trial's statistically significant results compared to industry standards, the high level of insider ownership, and growing anticipation for upcoming abstract presentations.

Lemonade, Inc. is a holding company, which engages in the provision of insurance services. The firm's products include renters and homeowners insurance, and pet insurance. It offers insurance coverage under the homeowners multi-peril, inland marine, and general liability lines of business. The company was founded by Daniel Asher Schreiber and Shai Wininger on June 17, 2015 and is headquartered in New York, NY.

Lemonade Inc

Lemonade is seeing significant investor attention following a strategic partnership with Tesla that provides insurance discounts for FSD-enabled vehicles, fueling community speculation about data-driven growth. While the stock has experienced notable volatility and high short interest, bulls are focused on the company's AI-native insurance platform and its potential to scale rapidly against traditional carriers.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

The XRP community is currently polarized as the Bitwise XRP ETF launch drives intense debate over its role in institutional adoption versus speculative price manipulation. Traders remain divided between those aggressively buying into the current price volatility and others expressing deep skepticism about the asset's long-term utility and historical price action.

Coda Octopus Group, Inc. engages in the developing, manufacturing, and marketing of subsea products. The firm operates through the following segments: Marine Technology Business (Products), Acoustics Sensors and Materials Business (PAL), and Defense Engineering Services Business. The Marine Technology Business segment develops solutions for subsea and underwater markets. The Acoustics Sensors and Materials Business segment engages in the provision of a comprehensive range of products and solutions, with a primary focus on medical imaging and Non-Destructive Testing. The Defense Engineering Services Business segment engages in defense contractors and designs, engineers, manufactures and supplies proprietary sub-assemblies for incorporation into broader mission critical defense systems. It also operates through the Americas, Europe, Australia or Asia, and Middle East or Africa geographical segments. The company was founded in 1994 and is headquartered in Orlando, FL.

Coda Octopus Group Inc.

Coda Octopus Group is gaining traction as investors focus on its proprietary real-time 3D sonar technology, which is increasingly critical for subsea infrastructure, defense, and maritime security. The community is actively discussing the stock's multi-bagger potential, high institutional interest, and the significant demand for its specialized equipment in global underwater operations.

Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. It delivers drugs into body compartments, such as the joint without any of the common issues with body compartment injections, such as systemic exposure. The firm focuses on arthritis, diabetic macular edema, and chronic pain programs. The company was founded by James A. Helliwell, John Salvatore Montalbano and Amanda Malone on May 12, 2011 and is headquartered in Victoria, Canada.

Eupraxia Pharmaceuticals Inc

Eupraxia Pharmaceuticals is capturing investor attention following consistently positive clinical data from its RESOLVE trial for EP-104GI in eosinophilic esophagitis, which validates the potential of its DiffuSphere delivery technology. The community is actively discussing the company's progress toward Phase 2b development and its growing pipeline, while analysts remain focused on the stock's long-term commercial potential and upcoming milestones.

Citi Trends, Inc. engages in the retail of urban fashion apparel, accessories, and home trends. It offers products under its Citi Steps and Red Ape brands. The company was founded in 1946 and is headquartered in Savannah, GA.

Citi Trends Inc

Citi Trends is currently trending as investors monitor its strategic turnaround plan, which includes store expansion and inventory management, alongside a raised fiscal outlook that has drawn significant attention from traders. The community is actively debating the company's long-term operational consistency and its ability to navigate current consumer spending headwinds.

What is DAG? In more traditional blockchains, the host provides the food/drinks (i.e resources) for this party. And when the guests arrive, the amount of resources can only accommodate so many people, the portions are small and then everything eventually runs out and the party ends. Think Constellation DAG like a potluck (a party where everyone brings food/drinks). With every added guest (node to the network), the more resources the party has to keep going. This is the nature of Constellation, a distributed system that scales horizontally.  Is Constellation a Blockchain? Not exactly. Although inspired by the principles of decentralization, many standard blockchains such as Bitcoin and Ethereum face scalability issues. This is why the next, generation of decentralized networks such as Hashgraph, IOTA, and Constellation have turned to DAG.  What is a Microservice? “Microservices” is an approach to application development in which a large application is built as a suite of modular services. Each module supports a specific business goal and uses a simple, well-defined interface to communicate with other sets of services. Uber, for example, is not a singular app purse. It is a unified app which means it is a single interface that brings together their driver app, their rider app, and their corporate team app.

Constellation

Constellation (DAG) is trending as investors focus on its potential as a specialized data-validation layer, particularly through its recent merger agreement with AI holding company AIAI and its history of contracts with U.S. government and defense agencies. The community is actively weighing the long-term utility of the Hypergraph architecture against the risks of a slow retail rollout, with many highlighting potential enterprise integration with major cloud providers as the primary catalyst for future growth.

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its products include Tandem Mobi System and t:slim X2 Insulin Pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.

Tandem Diabetes Care Inc

Tandem Diabetes is currently trending as investors react to a significant revenue beat and reaffirmed full-year sales guidance, with community sentiment shifting between optimistic growth potential and concerns over competitive pressure. Many traders are actively monitoring the stock's recent volatility and potential as a long-term acquisition target, while others debate the impact of new technology launches on its market share.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. (DJT) is trending as the community debates the geopolitical fallout of the ongoing conflict in the Middle East, specifically focusing on the closure of the Strait of Hormuz and the administration's call for international naval support. Investors are actively discussing the potential impact of these tensions on global energy prices, the effectiveness of proposed trade tariffs, and broader concerns regarding market stability as the administration navigates a complex coalition-building process.

QuickLogic Corp. operates as a semiconductor company, which designs, markets, and supports primarily Customer Specific Standard Products and secondarily, Field Programmable Gate Arrays, sensor software algorithms, software drivers, associated design software and programming hardware. It develops and markets low power customizable semiconductor and software algorithm solutions that enable customers to differentiate their products by adding new features, extending battery life, becoming more contextually aware and improving the visual experience with their mobile, consumer and enterprise products. The company was founded by John M. Birkner, Andrew K. Chan, and Hua-Thye Chua in 1988 and is headquartered in San Jose, CA.

Quicklogic Corp

QuickLogic is generating significant market interest due to new high-density eFPGA Hard IP contracts optimized for Intel's 18A technology, fueling speculation about strategic partnerships within the defense and AI accelerator sectors. Community members are actively debating the company's potential to secure its position in the domestic semiconductor supply chain while closely monitoring developments regarding Intel's foundry roadmap and upcoming contract milestones.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?

<ul class="summary-bullets"><li>Prasad, who oversees gene therapies in the FDA, told Bloomberg that regulation needs to evolve as science develops.</li><li>The executive is reportedly set to publish a paper in early November detailing the FDA’s new approach. &nbsp;</li></ul>A U.S. regulator reportedly plans to unveil a faster approach to approving custom gene-editing treatments for rare diseases.Vinay Prasad, who oversees gene therapies in the U.S. Food and Drug Administration, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-10-31/fda-clears-way-for-faster-personalized-gene-editing-treatments">told</a> Bloomberg that regulation needs to evolve as science develops. Prasad reportedly added that scientific advances like Nobel prize-winning CRISPR gene-editing technology have forced the agency to relax some of its strict rules.The agency is “going to be extremely flexible and work very fast with the scientists who want to bring these therapies to kids who need it,” Prasad told Bloomberg.The executive is reportedly set to publish a paper in early November detailing the FDA’s new approach. Prasad expects it will spark interest in developing treatment for rare diseases.<h2 class="st-heading-2">CRISPR’s Potential</h2>CRISPR gene editing is a technology that allows scientists to modify an organism's DNA precisely. It involves a guide RNA that directs a DNA-cutting enzyme to a specific target in the DNA for it to make a cut. The cell's natural repair process either inactivates the gene or allows scientists to insert a new piece of DNA.Earlier this year, an infant named KJ Muldoon, born with a rare genetic disorder called severe carbamoyl phosphate synthetase 1 (CPS1) deficiency, was successfully treated with a customized CRISPR gene editing therapy by a team at the Children’s Hospital of Philadelphia.The team behind the treatment of the infant is now designing clinical trials that can be used to gain FDA approval with a gene-editing platform that can be tailored for patients with different genetic mutations, Bloomberg reported. The team is asking for FDA permission to start clinical trials for a liver disorder known as phenylketonuria and urea cycle disorders, the report added.These diseases can be treated by editing genes in the liver, a known target for CRISPR, team members told Bloomberg.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ardelyx-shares-soar-premarket-as-ceo-sees-continued-demand-for-blockbuster-drug-ibsrela/cLGqRUcR3Ur">Ardelyx Shares Soar Premarket As CEO Sees Continued Demand For Blockbuster Drug Ibsrela</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the United States Food and Drug Administration (FDA) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

FDA To Ease Review Process For Life-Saving Gene-Editing Therapies: Report

Vinay Prasad told Bloomberg that the FDA is going to be “extremely flexible” regarding gene editing therapies. 

Equity

Vinay Prasad told Bloomberg that the FDA is going to be “extremely flexible” regarding gene editing therapies. 


UnitedHealth Lifts EPS Outlook Despite Mixed Q3 Results: ETFs in Focus

UNH posts mixed Q3 results with a revenue miss but lifts its 2025 EPS outlook, boosting interest in healthcare ETFs like IHF and XLV. 

ETFs to Watch Post JNJ's Q3 Earnings Surprise & Bullish Outlook

 JNJ's Q3 earnings beat and raised 2025 sales outlook could lift healthcare ETFs like IHE, XLV and IYH, heavily weighted toward the drugmaker.


BioXcel Therapeutics, Inc. (BTAI) announced on Wednesday that its BXCL501 demonstrated continued effects and consistent benefit with repeat dosing in the treatment of agitation associated with bipolar disorders or schizophrenia in a late-stage trial.BXCL501 is an investigational, orally dissolving film formulation of Dexmedetomidine, marketed by the company as Igalmi. While the primary objective of the trial was to ascertain the safety of the formulation in an at-home setting, the continued effects and consistent benefits observed with repeat dosing in the trial further support the potential of BXCL501 for use in the outpatient setting, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.bioxceltherapeutics.com/news-releases/news-release-details/bioxcel-therapeutics-reports-positive-topline-exploratory">said</a>.Shares of the company rose 3% in the pre-market session. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BTAI">BTAI stock</a> rose from ‘extremely bearish’ to ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘extremely low’ levels.BioXcel <a href="https://stocktwits.com/news-articles/markets/equity/bioxcel-sublingual-film-well-tolerated-in-bipolar-schizophrenia-trial-in-at-home-settings/chsU5sURdl5">reported</a> late last month that the drug was well-tolerated in the study. The company said that the data from the study will form the basis of a submission to the U.S. Food and Drug Administration (FDA) slated for the first quarter of 2026 and aimed at expanding the label for Dexmedetomidine in the at-home setting.“These positive results, along with the safety and tolerability data previously announced, reinforce BXCL501’s potential in the at-home setting where there is substantial unmet need with no FDA-approved options currently available,” said BioXcel CEO Vimal Mehta.The company said that a total of 246 patients were part of the trial, and 2,437 agitation episodes in 208 patients were treated. All patients were able to successfully self-administer the film, and an average of 11.7 agitation episodes were recorded per treated patient.Igalmi is already approved for the acute treatment of agitation associated with bipolar I or II disorder or schizophrenia in medically supervised settings.BTAI stock is down by 40% this year and by 59% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-edge-lower-ahead-of-inflation-data/chwkJpfRduc">Dow Futures Edge Lower As Investors Turn Cautious Ahead Of Inflation Data: ORCL, KLAR, HOOD, GME Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

BioXcel Stock Shoots Up 3% Pre-Market After Company Announces Positive Efficacy Data For Agitation Drug In Study

The company stated that the continued effects and consistent benefits observed with repeat dosing in the trial support the potential of BXCL501 for use in the outpatient setting. 

BioXcel Therapeutics, Inc. (BTAI) on Wednesday said that its late-stage trial evaluating the safety of the company’s BXCL501 as a treatment for agitation associated with bipolar disorders or schizophrenia in the at-home setting met its primary goal of being well-tolerated.BXCL501 is an investigational, orally dissolving film formulation of Dexmedetomidine. The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.bioxceltherapeutics.com/news-releases/news-release-details/bioxcel-therapeutics-announces-serenity-home-pivotal-phase-3">said</a> that the data from the study will form the basis of a submission to the U.S. Food and Drug Administration slated for the first quarter of 2026 and aimed at expanding the label for its dexmedetomidine sublingual film called Igalmi in the at-home setting.Igalmi is already approved for the acute treatment of agitation associated with bipolar I or II disorder or schizophrenia in medically supervised settings.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BTAI">BTAI stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:624/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_27_at_9_42_20_AM_png_54402b6e8c.webp" alt="BTAI's Sentiment Meter and Message Volume as of 9:42 a.m. ET on Aug. 27, 2025 | Source: Stocktwits" width="624" height="65"><figcaption>BTAI's Sentiment Meter and Message Volume as of 9:42 a.m. ET on Aug. 27, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user recommended buying the shares of the company.<stembedurl>https://stocktwits.com/Michael17711771/message/626688937</stembedurl>Another user opined that the study results are very promising long term.<stembedurl>https://stocktwits.com/They_call_me_tater_salad/message/626688733</stembedurl>BioXcel said that no discontinuations due to tolerability were observed in the arm of the study that received BXCL501.“By meeting its primary endpoint, the SERENITY At-Home Pivotal Phase 3 trial reinforces BXCL501’s potential to be safely used at home like it is already used in the previously FDA approved institutional setting. The unmet medical need in the at-home setting is significant with no FDA-approved treatments,” CEO Vimal Mehta said, while adding that the company believes the total addressable market is “significantly larger” than previously reported.The company said that a total of 246 patients were part of the trial, and 2,437 agitation episodes in 208 patients were treated. All patients were able to successfully self-administer the film, and an average of 11.7 agitation episodes were recorded per treated patient.The company said that available data demonstrate that treatment with BXCL501 regularly reduced symptoms of agitation throughout the trial. A greater percentage of patients experiencing mild, moderate, or severe agitation had full resolution of symptoms in the BXCL501 arm compared with placebo. Complete analyses of the full data set are ongoing and will be shared in time, the company said.BTAI stock is down by 24% this year and by 57% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/mannkind-united-therapeutics-expand-agreement-to-develop-second-investigational-molecule-together/chsURMTRdkC">MannKind, United Therapeutics Expand Agreement To Develop A Second Investigational Molecule Together</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

BioXcel’s Sublingual Film Well-Tolerated In Bipolar, Schizophrenia Trial In At-Home Settings, Retail Says Buy Now Or Regret Later

The company said that no discontinuations due to tolerability were observed in the arm of the study that received BXCL501.

FHLC
Fidelity MSCI Health Care Index ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest FHLC News

FHLCFidelity MSCI Health Care Index ETF